Table 2.

General characteristics from control, HFD, and HFD+ATZ (500 mg·kg⁻¹) treated mice.

Parameter	Groups
	CT	HFD	HFD+ATZ
Final systemic fasting glucose	103.3 ± 7.1	180.2 ± 13.86a	154.5 ± 5.65c
Food intake (g/body weight·day−1)	0.16 ± 0.00	0.081 ± 0.00a	0.08 ± 0.00
Final body weight (g)	32.19 ± 0.27	47.87 ± 1.41a	27.83 ± 0.20b,c
Δ body weight (final minus basal)	10.95 ± 0.51	25.69 ± 0.89a	7.99 ± 0.59b,c
Δ body weight (g) (final minus start of ATZ treatment)	3.78 ± 0.63	7.40 ± 0.77a	−7.31 ± 0.90b,c
Systolic blood pressure	118.0 ± 2.44	134.8 ± 5.16a	118.9 ± 3.27b
Epididymal adipose tissue (%)	1.36 ± 0.13	3.05 ± 0.19a	0.26 ± 0.06b,c
Perirenal adipose tissue (%)	0.67 ± 0.18	1.67 ± 0.22a	0.08 ± 0.02b,c
Brown adipose tissue (%)	0.32 ± 0.03	0.33 ± 0.01	0.84 ± 0.04b,c
Total cholesterol (mg·dL−1)	85.78 ± 2.84	135.6 ± 10.59a	110.3 ± 20.26
Triglycerides (mg·dL−1)	57.70 ± 8.6	83.98 ± 15.04	41.51 ± 8.7b
Nonesterified fatty acid (NEFA-mmol·L−1)	0.38 ± 0.04	0.60 ± 0.05a	0.17 ± 0.0b,c
Right tibia (mm)	18.1 ± 0.01	17.8 ± 0.03	18.4 ± 0.02
Total plasma proteins (mg·mL−1)	7.96 ± 0.07	8.13 ± 0.14	8.01 ± 0.05

Values represent the mean ± SEM. ANOVA one-way: ^ap < 0.05 HFD vs. CT. ^bp < 0.05 HFD+ATZ vs. HFD. ^cp < 0.05 HFD+ATZ vs. CT.